US Sees Increasing Diversity In Generic Formulations
While Next Five Years Could Be ‘Coming-Out Party’ For US Biosimilars
Executive Summary
Over the past five years, around a tenth of the US generics market’s total value has been ceded by oral solid dose generics to other formulations, IQVIA’s Doug Long told the AAM’s “Access!” annual meeting at the end of May.
You may also be interested in...
Lupin CEO Says Additional incentives Needed To Make US Manufacturing Viable
Lupin CEO Vinita Gupta has insisted that additional incentives are necessary to make local manufacturing in the US viable. The recently-launched podcast by the US Association for Accessible Medicines, with CEO Dan Leonard as the host, welcomed Gupta who shared details of Lupin’s strategy and how the company plans to keep a firm foot in affordable medicines.
FTC Urged To Investigate AbbVie’s IP Strategy On Humira
AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.
Teva Identifies ‘Problem Pattern’ Of Complex CRLs Ahead Of GDUFA III
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.